CheckMan Stock Market Overview

Quest Diagnostics Incorporated's recurring testing demand provides a foundation for growth through hospital partnerships, dialysis services, and advanced diagnostics. Their dialysis testing and advanced diagnostics add growth opportunities, although their value ultimately depends on execution and reimbursement. So far, DGX's cash flows seem to be benefiting from the acquisition strategy, but if this falters, it may lead to write-downs of its sizable goodwill on the balance sheet.

Warren Buffett built Berkshire Hathaway into a dividend-collecting machine even though the company refuses to pay one itself, and five of his biggest holdings are quietly handing shareholders more cash every single year.

Regulatory tightening and liquidity shocks have driven losses, but Lufax's tangible equity remains nearly 9x the share price, suggesting deep value. LU's parent, Ping An, provides significant backing, and internal control issues have been addressed, positioning LU for a potential Hong Kong trading resumption. A stop of trading suspension on the Hong Kong stock exchange may be an important catalyst.

Native AI capabilities will help connect and simplify revenue cycle workflows to help healthcare organizations optimize financial performance and enhance patient financial experiences ORLANDO, Fla., Sept. 23, 2026 /PRNewswire/ -- Oracle Health and Life Sciences Summit -- Oracle Health today announced new AI capabilities across its revenue cycle management portfolio that are planned to be released in the coming months to help healthcare organizations in the US limit reimbursement problems early in the patient and payment journey.

Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027 Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that Health Canada has cleared the Company's Clinical Trial Application (CTA) for ASCENTRA-UC, its global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis (UC).

Intel is parlaying its strength into the agentic AI growth inflection, driven by surging demand for data center CPUs. INTC's foundry business losses are narrowing, with break-even targeted by end-2028, reversing years of severe gloom. Despite a 42x 2028E PE, robust earnings recovery and multiple growth levers—including pricing, volume, and advanced packaging—support maintaining a Buy rating.

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Alibaba Group Holding Limited (“Alibaba” or the “Company”) (NYSE: BABA) on behalf of investors that purchased or otherwise acquired Alibaba securities between June 26, 2025 and June 24, 2026 (the “Class Period”).

China Automotive Systems is upgraded to BUY after strong 1H26 results and a compelling valuation at 1.2x EV/EBITDA versus peers at 5.6x. EPS segment drives margin expansion and profit growth, now 46.8% of sales, with robust demand from both domestic and overseas automakers. Management raised 2026 revenue guidance to $850 million, supported by new European contracts and a Mexico plant adding 1 million units of capacity.

Palantir stock is slightly higher this year even as business growth accelerates. The FAA's AI air traffic control system could be another revenue growth opportunity.

A defense analyst warned that China may be watching gleefully as the Pentagon scrambles to restock two weapons classes critical to any future great-power fight.